Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of ravulizumab in clinically diagnosed aHUS (Japan)
jRCT2041250140Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ravulizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Improvement in platelet count during 26-week treatment. Started Dec 2025; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on jRCT2041250140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250140.